<code id='2E236D4993'></code><style id='2E236D4993'></style>
    • <acronym id='2E236D4993'></acronym>
      <center id='2E236D4993'><center id='2E236D4993'><tfoot id='2E236D4993'></tfoot></center><abbr id='2E236D4993'><dir id='2E236D4993'><tfoot id='2E236D4993'></tfoot><noframes id='2E236D4993'>

    • <optgroup id='2E236D4993'><strike id='2E236D4993'><sup id='2E236D4993'></sup></strike><code id='2E236D4993'></code></optgroup>
        1. <b id='2E236D4993'><label id='2E236D4993'><select id='2E236D4993'><dt id='2E236D4993'><span id='2E236D4993'></span></dt></select></label></b><u id='2E236D4993'></u>
          <i id='2E236D4993'><strike id='2E236D4993'><tt id='2E236D4993'><pre id='2E236D4993'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge